236 related articles for article (PubMed ID: 21996089)
21. Prognostic significance of standardised uptake value (SUV
Yilmaz Demirci N; Yilmaz Ü; Biner Uslu I; Dikmen A; Yılmaz A; Erdoğan Y
Eur J Cancer Care (Engl); 2017 Sep; 26(5):. PubMed ID: 26988938
[TBL] [Abstract][Full Text] [Related]
22. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
23. FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer.
Kwon W; Howard BA; Herndon JE; Patz EF
J Thorac Oncol; 2015 Jun; 10(6):897-902. PubMed ID: 25811445
[TBL] [Abstract][Full Text] [Related]
24. The prognostic role of PET/CT in small-cell lung cancer.
Budak E; Yanarateş A; Akgün A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):9-13. PubMed ID: 31865009
[TBL] [Abstract][Full Text] [Related]
25. Difference in prognostic values of maximal standardized uptake value on fluorodeoxyglucose-positron emission tomography and cyclooxygenase-2 expression between lung adenocarcinoma and squamous cell carcinoma.
Shimizu K; Maeda A; Yukawa T; Nojima Y; Saisho S; Okita R; Nakata M
World J Surg Oncol; 2014 Nov; 12():343. PubMed ID: 25392182
[TBL] [Abstract][Full Text] [Related]
26. Predictive and prognostic value of early response assessment using 18FDG-PET in advanced non-small cell lung cancer patients treated with erlotinib.
Tiseo M; Ippolito M; Scarlattei M; Spadaro P; Cosentino S; Latteri F; Ruffini L; Bartolotti M; Bortesi B; Fumarola C; Caffarra C; Cavazzoni A; Alfieri RR; Petronini PG; Bordonaro R; Bruzzi P; Ardizzoni A; Soto Parra HJ
Cancer Chemother Pharmacol; 2014 Feb; 73(2):299-307. PubMed ID: 24258456
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of SUVmax and metabolic tumor volume on 18F-FDG PET/CT in early stage non-small cell lung cancer patients without LN metastasis.
Yoo IeR; Chung SK; Park HL; Choi WH; Kim YK; Lee KY; Wang YP
Biomed Mater Eng; 2014; 24(6):3091-103. PubMed ID: 25227018
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of total lesion glycolysis in patients with advanced non-small cell lung cancer receiving chemotherapy.
Zaizen Y; Azuma K; Kurata S; Sadashima E; Hattori S; Sasada T; Imamura Y; Kaida H; Kawahara A; Kinoshita T; Ishibashi M; Hoshino T
Eur J Radiol; 2012 Dec; 81(12):4179-84. PubMed ID: 22884163
[TBL] [Abstract][Full Text] [Related]
29. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer.
Lee YJ; Cho A; Cho BC; Yun M; Kim SK; Chang J; Moon JW; Park IK; Choi HJ; Kim JH
Clin Cancer Res; 2009 Apr; 15(7):2426-32. PubMed ID: 19318478
[TBL] [Abstract][Full Text] [Related]
30. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer.
Goodgame B; Pillot GA; Yang Z; Shriki J; Meyers BF; Zoole J; Gao F; Dehdashti F; Patterson A; Siegel BA; Govindan R
J Thorac Oncol; 2008 Feb; 3(2):130-4. PubMed ID: 18303432
[TBL] [Abstract][Full Text] [Related]
31. The maximum standardized uptake value of fluorodeoxyglucose positron emission tomography of the primary tumour is a good predictor of pathological nodal involvement in clinical N0 non-small-cell lung cancer.
Miyasaka Y; Suzuki K; Takamochi K; Matsunaga T; Oh S
Eur J Cardiothorac Surg; 2013 Jul; 44(1):83-7. PubMed ID: 23233074
[TBL] [Abstract][Full Text] [Related]
32. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
Dooms C; van Baardwijk A; Verbeken E; van Suylen RJ; Stroobants S; De Ruysscher D; Vansteenkiste J
J Thorac Oncol; 2009 Jul; 4(7):822-8. PubMed ID: 19487964
[TBL] [Abstract][Full Text] [Related]
33. FDG-PET Predicts Pain Response and Local Control in Palliative Radiotherapy With or Without Systemic Treatment in Patients With Bone Metastasis From Non-small-cell Lung Cancer.
Zhao F; Ding G; Huang W; Li M; Fu Z; Yang G; Kong L; Zhang Y; Yu J
Clin Lung Cancer; 2015 Nov; 16(6):e111-9. PubMed ID: 25736696
[TBL] [Abstract][Full Text] [Related]
34. Early metabolic response on 18F-fluorodeoxyglucose-positron-emission tomography/computed tomography after concurrent chemoradiotherapy for advanced stage III non-small cell lung cancer is correlated with local tumor control and survival.
Jeong JU; Chung WK; Nam TK; Song JY; Yoon MS; Kim YC; Kim KS; Oh IJ; Ban HJ; Kwon SY; Bom HS; Ahn SJ
Anticancer Res; 2014 May; 34(5):2517-23. PubMed ID: 24778069
[TBL] [Abstract][Full Text] [Related]
35. Baseline SUVmax at PET-CT in stage IIIA non-small-cell lung cancer patients undergoing surgery after neoadjuvant therapy: prognostic implication focused on histopathologic subtypes.
Lee HY; Lee KS; Park J; Han J; Kim BT; Kwon OJ; Ahn YC; Ahn MJ; Park K; Kim J; Shim YM
Acad Radiol; 2012 Apr; 19(4):440-5. PubMed ID: 22265854
[TBL] [Abstract][Full Text] [Related]
36. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
[TBL] [Abstract][Full Text] [Related]
37. Combined prognostic value of the SUVmax derived from FDG-PET and the lymphocyte-monocyte ratio in patients with stage IIIB-IV non-small cell lung cancer receiving chemotherapy.
Zhao K; Wang C; Shi F; Huang Y; Ma L; Li M; Song Y
BMC Cancer; 2021 Jan; 21(1):66. PubMed ID: 33446134
[TBL] [Abstract][Full Text] [Related]
38. Prognostic importance of
Kanyilmaz G; Benli Yavuz B; Aktan M; Sahin O
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):20-26. PubMed ID: 31668790
[TBL] [Abstract][Full Text] [Related]
39. Use of maximum standardized uptake value on fluorodeoxyglucose positron-emission tomography in predicting lymph node involvement in patients with primary non-small cell lung cancer.
Muto J; Hida Y; Kaga K; Ohtaka K; Okamoto S; Tamaki N; Nakada-Kubota R; Hirano S; Matsui Y
Anticancer Res; 2014 Feb; 34(2):805-10. PubMed ID: 24511016
[TBL] [Abstract][Full Text] [Related]
40. Outcome analysis of (18)F-fluorodeoxyglucose positron-emission tomography in patients with lung cancer after partial volume correction.
Ohtaka K; Hida Y; Kaga K; Okamoto S; Shiga T; Tamaki N; Muto J; Nakada-Kubota R; Hirano S; Matsui Y
Anticancer Res; 2013 Nov; 33(11):5193-8. PubMed ID: 24222169
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]